ArticleBritish journal of pharmacology1999
Mibefradil (Ro 40-5967) inhibits several Ca2+ and K+ currents in human fusion-competent myoblasts.
Article in British journal of pharmacology, 1999. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 54 citations in OpenAlex.
- Clinical and experimental insight into pathophysiology, comorbidity and therapy of absence seizures.Brain : a journal of neurology · 2020Review
- T-type calcium channels in synaptic plasticity.Channels (Austin, Tex.) · 2017Review
- T-Type Calcium Channel: A Privileged Gate for Calcium Entry and Control of Adrenal Steroidogenesis.Frontiers in endocrinology · 2016Review
- The many faces of T-type calcium channels.Pflugers Archiv : European journal of physiology · 2014Review
- The mechanism of increased postnatal heart rate and sinoatrial node pacemaker activity in mice.The journal of physiological sciences : JPS · 2013Article
- Article
- Selective T-type calcium channel block in thalamic neurons reveals channel redundancy and physiological impact of I(T)window.The Journal of neuroscience : the official journal of the Society for Neuroscience · 2010Article
- Neuroprotective effects of blockers for T-type calcium channels.Molecular neurodegeneration · 2009Article
- On the fate of skeletal myoblasts in a cardiac environment: down-regulation of voltage-gated ion channels.The Journal of physiology · 2004Article
- Low-voltage-activated ("T-Type") calcium channels in review.Journal of bioenergetics and biomembranes · 2003Review
- The sources and sequestration of Ca(2+) contributing to neuroeffector Ca(2+) transients in the mouse vas deferens.The Journal of physiology · 2003Article
- Modulation and pharmacology of low voltage-activated ("T-Type") calcium channels.Journal of bioenergetics and biomembranes · 2003Review
- T-type alpha 1H Ca2+ channels are involved in Ca2+ signaling during terminal differentiation (fusion) of human myoblasts.Proceedings of the National Academy of Sciences of the United States of America · 2000Article
- High affinity interaction of mibefradil with voltage-gated calcium and sodium channels.British journal of pharmacology · 2000Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
1. The effect of mibefradil (Ro 40-5967), an inhibitor of T-type Ca2+ current (I(Ca)(T)), on myoblast fusion and on several voltage-gated currents expressed by fusion-competent myoblasts was examined. 2. At a concentration of 5 microM, mibefradil decreases myoblast fusion by 57%. At this concentration, the peak amplitudes of I(Ca)(T) and L-type Ca2+ current (I(Ca)(L)) measured in fusion-competent myoblasts are reduced by 95 and 80%, respectively. The IC50 of mibefradil for I(Ca)(T) and I(Ca)(L) are 0.7 and 2 microM, respectively. 3. At low concentrations, mibefradil increased the amplitude of I(Ca)(L) with respect to control. 4. Mibefradil blocked three voltage-gated K+ currents expressed by human fusion-competent myoblasts: a delayed rectifier K+ current, an ether-à-go-go K+ current, and an inward rectifier K+ current, with a respective IC50 of 0.3, 0.7 and 5.6 microM. 5. It is concluded that mibefradil can interfere with myoblast fusion, a mechanism fundamental to muscle growth and repair, and that the interpretation of the effect of mibefradil in a given system should take into account the action of this drug on ionic currents other than Ca2+ currents.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.